Enlivex Therapeutics Ltd
About
Enlivex Therapeutics Ltd (NASDAQ:ENLV) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 23 2026
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
Apr 21 2026
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Apr 8 2026
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares
Mar 24 2026
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
Mar 23 2026
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Financials
Revenue
$0
Market Cap
$227.83 M
P/E Ratio
0.04
EPS
25.48